Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 23, 2018. The report details a significant regulatory milestone for GSK's vaccine portfolio, specifically the approval of Shingrix in Europe and Japan.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on regulatory approvals rather than a financial statement.
Material Changes and Regulatory Approvals
- European Approval: The European Commission approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN) in adults aged 50 years or older.
- Japanese Approval: The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Shingrix for the prevention of shingles in adults aged 50 years or older.
- Commercial Structure: In Japan, the vaccine is registered to Japan Vaccine Co., Ltd., a joint venture between GSK and Daiichi Sankyo Co., Ltd.
- Clinical Efficacy: Shingrix demonstrated efficacy greater than 90% across all age groups studied in pooled analysis of pivotal studies (ZOE-50 and ZOE-70), based on a Phase III program involving more than 38,000 people.
Outlook, Risks, and Management Commentary
Management, represented by Dr. Thomas Breuer (Senior Vice President and Chief Medical Officer of GSK Vaccines), characterized the approvals as recognition of a significant scientific advance. The vaccine is designed to overcome the decline in immunity associated with aging. Shingrix is already approved in the US and Canada (October 2017) and is the preferred vaccine recommended by the US CDC for adults aged 50 and older.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the company's 2017 Annual Report on Form 20-F. Safety information notes that vaccination may not protect all individuals and lists common side effects such as pain, redness, and swelling at the injection site.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Shingrix in the European and Japanese markets.
- Review the terms of the joint venture with Daiichi Sankyo Co., Ltd. regarding revenue sharing in Japan.
- Assess the competitive landscape in Europe and Japan, particularly against existing shingles vaccines.
- Monitor post-marketing safety data and real-world efficacy reports following the new approvals.
- Check the 2017 Annual Report on Form 20-F for detailed financial context and principal risk factors referenced in this filing.